View Item 

Show simple item record

Vaccine effectiveness against COVID-19 among symptomatic persons aged ≥12 years with reported contact with COVID-19 cases, February–September 2021
dc.contributor.authorChung, Jessie R.
dc.contributor.authorKim, Sara S.
dc.contributor.authorBelongia, Edward A.
dc.contributor.authorMcLean, Huong Q.
dc.contributor.authorKing, Jennifer P.
dc.contributor.authorNowalk, Mary Patricia
dc.contributor.authorZimmerman, Richard K.
dc.contributor.authorMoehling Geffel, Krissy
dc.contributor.authorMartin, Emily T.
dc.contributor.authorMonto, Arnold S.
dc.contributor.authorLamerato, Lois E.
dc.contributor.authorGaglani, Manjusha
dc.contributor.authorHoffman, Eric
dc.contributor.authorVolz, Marcus
dc.contributor.authorJackson, Michael L.
dc.contributor.authorJackson, Lisa A.
dc.contributor.authorPatel, Manish M.
dc.contributor.authorFlannery, Brendan
dc.date.accessioned2022-07-05T21:01:57Z
dc.date.available2023-08-05 17:01:56en
dc.date.available2022-07-05T21:01:57Z
dc.date.issued2022-07
dc.identifier.citationChung, Jessie R.; Kim, Sara S.; Belongia, Edward A.; McLean, Huong Q.; King, Jennifer P.; Nowalk, Mary Patricia; Zimmerman, Richard K.; Moehling Geffel, Krissy; Martin, Emily T.; Monto, Arnold S.; Lamerato, Lois E.; Gaglani, Manjusha; Hoffman, Eric; Volz, Marcus; Jackson, Michael L.; Jackson, Lisa A.; Patel, Manish M.; Flannery, Brendan (2022). "Vaccine effectiveness against COVID-19 among symptomatic persons aged ≥12 years with reported contact with COVID-19 cases, February–September 2021." Influenza and Other Respiratory Viruses 16(4): 673-679.
dc.identifier.issn1750-2640
dc.identifier.issn1750-2659
dc.identifier.urihttps://hdl.handle.net/2027.42/172987
dc.description.abstractBackgroundIndividuals in contact with persons with COVID-19 are at high risk of developing COVID-19; protection offered by COVID-19 vaccines in the context of known exposure is poorly understood.MethodsSymptomatic outpatients aged ≥12 years reporting acute onset of COVID-19-like illness and tested for SARS-CoV-2 between February 1 and September 30, 2021 were enrolled. Participants were stratified by self-report of having known contact with a COVID-19 case in the 14 days prior to illness onset. Vaccine effectiveness was evaluated using the test-negative study design and multivariable logistic regression.ResultsAmong 2229 participants, 283/451 (63%) of those reporting contact and 331/1778 (19%) without known contact tested SARS-CoV-2-positive. Adjusted vaccine effectiveness was 71% (95% confidence interval [CI], 49%–83%) among fully vaccinated participants reporting a known contact versus 80% (95% CI, 72%–86%) among those with no known contact (p-value for interaction = 0.2).ConclusionsThis study contributes to growing evidence of the benefits of vaccinations in preventing COVID-19 and support vaccination recommendations and the importance of efforts to increase vaccination coverage.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherCOVID-19
dc.subject.otherSARS-CoV-2
dc.subject.othervaccine effectiveness
dc.titleVaccine effectiveness against COVID-19 among symptomatic persons aged ≥12 years with reported contact with COVID-19 cases, February–September 2021
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172987/1/irv12973.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172987/2/irv12973_am.pdf
dc.identifier.doi10.1111/irv.12973
dc.identifier.sourceInfluenza and Other Respiratory Viruses
dc.identifier.citedreferenceKaslow DC. Force of infection: A determinant of vaccine efficacy? NPJ Vaccines. 2021; 6 ( 1 ): 51. doi: 10.1038/s41541-021-00316-5
dc.identifier.citedreferenceKim SS, Chung JR, Belongia EA, et al. mRNA vaccine effectiveness against COVID-19 among symptomatic outpatients aged ≥16 years in the United States, February - May 2021. J Infect Dis. 2021.
dc.identifier.citedreferenceWoodworth KR, Moulia D, Collins JP, et al. The advisory committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in children Aged 5-11 years - United States, November 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 ( 45 ): 1579 – 1583. doi: 10.15585/mmwr.mm7045e1
dc.identifier.citedreferenceMbaeyi S, Oliver SE, Collins JP, et al. The advisory committee on immunization practices’ interim recommendations for additional primary and booster doses of COVID-19 vaccines - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 ( 44 ): 1545 – 1552. doi: 10.15585/mmwr.mm7044e2
dc.identifier.citedreferenceCenters for Disease Control and Prevention. COVID-19 vaccine booster shots. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html. Accessed November 22 2021.
dc.identifier.citedreferenceTang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021; 27 ( 12 ): 2136 – 2143. doi: 10.1038/s41591-021-01583-4
dc.identifier.citedreferenceNanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant - National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 ( 34 ): 1163 – 1166. doi: 10.15585/mmwr.mm7034e3
dc.identifier.citedreferenceTartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398 ( 10309 ): 1407 – 1416. doi: 10.1016/S0140-6736(21)02183-8
dc.identifier.citedreferenceKang M, Xin H, Yuan J, et al. Transmission dynamics and epidemiological characteristics of Delta variant infections in China. medRxiv. 2021. 2021.08.12.21261991
dc.identifier.citedreferenceLuo L, Liu D, Liao X, et al. Contact settings and risk for transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China: A prospective cohort study. Ann Intern Med. 2020; 173 ( 11 ): 879 – 887. doi: 10.7326/M20-2671
dc.identifier.citedreferenceCenters for Disease Control and Prevention. COVID data tracker|variant proportions. Available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Accessed November 16 2021.
dc.identifier.citedreferenceJackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013; 31 ( 17 ): 2165 – 2168. doi: 10.1016/j.vaccine.2013.02.053
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines Currently approved or authorized in the United States. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https-3A-2F-2Fwww.cdc.gov-2Fvaccines-2Fcovid-19-2Finfo-by-product-2Fclinical-considerationshtml#dosing-schedule. Accessed November 16 2021.
dc.identifier.citedreferenceChung JR, Kim SS, Jackson ML, et al. Clinical symptoms among ambulatory patients tested for SARS-CoV-2. Open forum Infect Dis. 2021; 8: ofaa576. doi: 10.1093/ofid/ofaa576
dc.identifier.citedreferenceThompson HA, Mousa A, Dighe A, et al. Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) setting-specific transmission rates: A systematic review and meta-analysis. Clin Infect Dis. 2021; 73 ( 3 ): e754 - e764. doi: 10.1093/cid/ciab100
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
irv12973.pdf
Size:
1.546MB
Format:
PDF
View/Open
Name:
irv12973_am.pdf
Size:
706.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.